Fig. 1From: GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling offMeta-analyses of cardiorenal effects exerted by GLP-1RA and SGLT-2 inhibitors in patients with or without type 2 diabetes. HR hazard ratio, CI confidence intervals. The results are based on data in Ref. [7, 8, 11]Back to article page